Caron Introduces New Environmental Test Chambers and Refrigerated Incubators - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Caron Introduces New Environmental Test Chambers and Refrigerated Incubators



Caron's new environmentally controlled stability chambers include large-capacity environmental chambers (7000 Series) and refrigerated incubators (7001 Series) in two-door (50 cu. ft.) and three-door (75 cu. ft.) configurations.

The new stability chambers are designed in accordance with FDA ICH Q1A Guidelines and can be used for numerous customer applications, including shelf-life studies, stability and package testing, and temperature-elevation studies. The stability chambers have several new features, including humidity control, self-closing doors with locks, CFC-free foam insulation, and a full-color user interface. These new design features help yield up to 71% in energy savings. The environmental chambers and refrigerated incubators also have a 7” color touchscreen that has easy-to-read icons and a display that can be operated with gloves on. Both products are constructed of stainless steel, making them easy to clean and highly resistant to corrosion.

Source:Caron

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here